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grade with 90% specificity and 58% sensitivity, whereas a PDFF increase of 5.6% identified those with increased steatosis grade with 90% specificity and 57% sensitivity.
Conclusions:
Based on data from a phase 2 randomized controlled trial of adults with NASH, PDFF estimated by MRI scanners of different field strength and at different sites, accurately classifies grades and changes in hepatic steatosis when histologic analysis of biopsies is used as a reference. with N-3 fish oil vs placebo for one year), subjects treated with N3 lost more weight and showed a greater decrease in PDFF than those treated with placebo, although there were no differences in Therefore, the purpose of this study was to assess cross-sectional and longitudinal diagnostic performance of PDFF to grade hepatic steatosis in adults using centrally-scored histology as reference. To do this, we performed a prospectively-designed study of PDFF 
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MATERIALS AND METHODS

Study design
MRI was offered at baseline and end-of-treatment (EOT) to adults participating in the FLINT trial. PDFF was a secondary imaging endpoint, for which histologic hepatic steatosis grade served as the reference standard.
Eligibility criteria for the FLINT trial are published elsewhere [23] ; all subjects were diagnosed with NASH based on local histology review of a standard-of-care liver biopsy.
Inclusion criteria for the liver MRI portion of the FLINT trial were that the subject was enrolled, and that the subject was willing and able to complete both MRI exams The FLINT trial, including the MRI portion, was approved by an Institutional Review
Board at each participating clinical trial site, and was in compliance with the Health Insurance Portability and Accountability Act. All subjects enrolled in the FLINT trial signed informed consent for MRI exams.
All authors had access to the study data and have reviewed and approved the final manuscript.
MRI clinical trial site qualification
The MRI portion of this study was managed by the NASH CRN Radiology Coordinating 
MRI exams
Seven of the eight participating FLINT clinical trial sites contributed MRI data to this study using 1.5T (three sites) and 3T (four sites) MR scanners ( Table 1) . At each clinical trial site, only a single scanner was used so that longitudinal instrument-dependent measurement variability would be minimized. PDFF reproducibility has been demonstrated in two studies across different clinical trial sites, and for both field strengths used in this study [13, 14] .
For each MRI exam, an advanced, non-contrast, breath-hold, magnitude-based, gradientrecalled-echo (GRE), two-dimensional axial sequence was obtained of the entire liver using a M A N U S C R I P T
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22 torso array coil centered over the liver. T1 effects that could cause subject-or scanner-dependent bias were minimized using a low flip angle (ten degrees) and a repetition time (TR) of ≥ 120 ms.
Six echoes were collected at alternately out-of-phase and in-phase echo times (TEs) for the water and main fat peaks to permit PDFF quantification while accounting for subject-based T2* effects 
Comparison of histologic steatosis grade and PDFF
PDFF, and histologic steatosis percentage (and grade) both assess liver fat, but they do so M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
in very different ways. Histologic steatosis assessment yields a percentage of hepatocytes that
show fat globules on H&E stain (from whence is derived a steatosis grade from 0 to 3), whereas PDFF estimates a ratio of observable MRI signal from fat, compared to all observable MRI signal (from both fat and water). Thus, if all examined hepatocytes were seen to be filled with 50% fat globules, the histologic steatosis percentage would be 100% since all cells show fat globules, and the steatosis grade would be 3, but the MRI PDFF percentage would be, ignoring technical factors for the moment, something like 50%. Thus, we see in practice that PDFF percentages typically are somewhat less than half of histologic steatosis percentages.
Central histological analysis
Biopsies were reviewed by the pathologists of the NASH CRN Pathology Committee who provided central histology assessment by consensus at a multi-head microscope.
Pathologists were blinded to all clinical information, including participation in this study.
Steatosis grade was provided according to the standardized NASH CRN histological NAFLD scoring system (proportion of hepatocytes containing fat macrovesicles: grade 0 for < 5%, grade 1 for 5 to 33%, grade 2 for > 33 to 66%, and grade 3 for > 66% [25]). Other centrally scored features that were evaluated in this study were lobular inflammation, portal inflammation, hepatocellular ballooning, fibrosis stage, and NAFLD Activity Score (NAS).
Blinding
RCC analysts and other staff at the RCC were blinded to histology results, and pathologists were blinded to imaging results. RCC analysts were blinded to treatment assignment.
Other data
Subject demographics, laboratory, anthropomorphic measurements, and medical history M A N U S C R I P T curves using a jack-knife procedure and 95% CIs were estimated for each of these dichotomizations [26] . Cut-off PDFF values were estimated using the lowest threshold value for which there was ≥ 90% specificity to distinguish between these dichotomized categories.
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Sensitivity, positive predictive values (PPVs), and negative predictive valves (NPVs) were calculated along with 95% confidence intervals (CIs) fixing specificity at 90%.
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RESULTS
Of 283 adults enrolled in the FLINT trial from March 16, 2011 to December 3, 2012 at eight participating FLINT clinical trial sites, 113 (40%) had MRI and liver biopsy at baseline, 85
(30%) had MRI and liver biopsy at EOT, and 78 (28%) had MRI and liver biopsy at both time points. One subject with a baseline MRI but without a centrally-read baseline liver biopsy was excluded from the analysis. All baseline MRIs were performed prior to randomization and occurred an average of 51 days following baseline biopsy. Follow-up MRIs were performed an average of two days after follow-up biopsy, and were performed from 29 days before to 78 days after biopsy.
Cohort baseline population characteristics are summarized in Table 2 . Subjects who had, vs did not have MRIs had significantly (p < 0.05) lower mean aspartate aminotransferase, alkaline phosphatase, weight, BMI and prevalence of hyperlipidemia and hypertension.
Additionally, the 78 subjects with both paired MRIs and paired biopsies vs the 204 subjects without, had lower (p < 0.05) mean AST, ALT and alkaline phosphatase at baseline.
Cross-sectional analysis
The distribution of PDFF at baseline is shown in Figure 1 : PDFF mean was 18.6%±9.6%, and ranged from 3.7% to 49.3%. Diagnostic accuracy of change in PDFF vs change in histologic hepatic steatosis grade from baseline to EOT is summarized in Table 4 . At EOT, 42% of paired biopsies had improvement in steatosis grade, 49% had no change, and 9% had worsening. The AUROC using PDFF change to classify histologic hepatic steatosis grade improvement and worsening, respectively, were 0.81 (95% CI, 0.71-0.91) and 0.81 (95% CI, 0.63-0.99). Cut-off values for M A N U S C R I P T
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PDFF change at 90% specificity were -5.1% for improvement and +5.6% for worsening hepatic steatosis grade.
DISCUSSION
We compared PDFF to histologic hepatic steatosis grade at baseline, and change in PDFF to change in histologic hepatic steatosis grade from baseline to EOT. We found that PDFF correlates well with histologic hepatic steatosis grade cross-sectionally, and that change in PDFF correlates well with change in histologic hepatic steatosis grade longitudinally.
ROC analysis at baseline yielded PDFF cutoffs predicting histologic hepatic steatosis grade that are similar to those reported in the literature for a single-center study. We found that at 90% specificity, PDFF cut-off values were 16.3% (83% sensitivity) and 21.7% (84% sensitivity)
for discrimination of histologic steatosis grades 0-1 from 2-3, and grades 0-2 from 3, The AUROC of PDFF for classifying longitudinal change in steatosis is 0.81, which is inferior to its cross-sectional performance at baseline. The lower AUROC for change may reflect the 'noisiness' of histologic grading as a marker of steatosis, an effect which is amplified when differences in PDFF are compared to differences in histologic steatosis grade.
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Hepatic steatosis may also be assessed non-invasively by CAP (a transient elastographyderived controlled attenuation parameter), which is an estimate of total ultrasound attenuation
. Although we did not perform a direct comparison of CAP and PDFF, the accuracy of MRI to estimate PDFF has been reported to be higher than that of CAP, using histology as reference
Strengths of this study are that the cohort of patients that was studied was wellcharacterized, with a racial/ethnic makeup representative of patients diagnosed with NASH in the United States; that subjects enrolled in this study had both pre-and post-treatment biopsy;
that histology was scored centrally by the NASH CRN Pathology Committee; and that a range of MRI scanner manufacturers at two field strengths and across multiple study sites were utilized.
Thus, our study results are likely to be generalizable to the entire adult NASH population in the United States, while also providing compelling evidence that MRI-PDFF can be applied successfully in multi-center trials.
A major limitation of this study was that not all subjects enrolled in the FLINT trial had
MRIs. Only 40% of randomized subjects had an MRI at baseline and only 28% had paired EOT and baseline MRIs. Participation in the MRI study was reduced because the MRI qualification process at each clinic was completed after the start of enrollment into the trial. Participation rates into the MRI study varied widely at the nine study sites, ranging from 0 to 84%. In addition, subjects who had the MRI weighed significantly less than those who did not participate; this may be because the heaviest FLINT participants were too large to undergo MRI. Also, significantly lower mean alanine aminotransferase and aspartate aminotransferase and lower rates of hyperlipidemia and hypertension were seen at baseline in those who did vs did not participate in the MRI study suggesting a less severe group in those who participated. Our results could be M A N U S C R I P T
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29 biased if the relationships between MRI-PDFF and histologic features varied in those who participated vs did not participate in the MRI study.
Another limitation was that relatively few subjects of non-White race were included. This was unavoidable since NASH is relatively uncommon in non-Whites, and the racial and ethnic diversity of our study population reflects that seen in the national prevalence of NASH. Our study also did not include children, as the FLINT trial enrolled only adults; thus multi-center validation studies of MRI PDFF in children are needed. Finally, potentially confounding factors such as those in Table 2 were not investigated because the study was not powered to permit M A N U S C R I P T 1.1±0. 6 1.2±0.6 0.86 Notes: Plus-minus values are means±SD; BMI = body mass index; PDFF = proton density fat fraction; SD = standard deviation. * Two study sites with combined 55 randomized subjects did not obtain MRIs 1
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Fibrosis was assessed on a scale of 0 to 4, with higher scores indicating more severe fibrosis 2 NAS was assessed on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure are steatosis (assessed on a scale of 0 to 3), lobular inflammation (assessed on a scale of 0 to 3), and hepatocellular ballooning (assessed on a scale of 0 to 2) 3
Portal inflammation was assessed on a scale of 0 to 2 with higher scores indicating more severe inflammation M A N U S C R I P T 
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